Demographic and clinical characteristics of the 430 patients who had not achieved a CR at day 100 post transplant based on the presence or absence of a complete response
| . | Continued response (n = 167) . | No continued response (n = 263) . |
|---|---|---|
| Variables . | Median (range) . | Median (range) . |
| Age, y | 60 (32-75) | 60 (29-74) |
| Male, n,( %) | 92 (55%) | 176 (62%) |
| PCLI | ||
| At diagnosis | 0.4 (0-4) | 0.6 (0-14.4) |
| At transplant | 0.3 (0-6) | 0.2 (0-11) |
| Serum M spike | ||
| At diagnosis | 3.7 (0-9) | 3.1 (0-8.5) |
| At transplant | 1 (0-5.1) | 1 (0-6.9) |
| Urine M spike | ||
| At diagnosis | 0.4 (0-15.5) | 0.7 (0-22.6) |
| At transplant | 0.04 (0-10) | 0.09 (0-10) |
| BMPC, % | ||
| At diagnosis | 50 (2- 95) | 50 (2-100) |
| At transplant | 11 (1-95) | 17 (1-100) |
| LDH | ||
| At diagnosis | 150 (62-464) | 152 (51-617) |
| At transplant | 205 (68-1103) | 203 (74-729) |
| β2-microglobulin | ||
| At diagnosis | 3.6 (1-1447) | 3.9 (1-21) |
| At transplant | 2.4 (1-34) | 2.5 (1-34) |
| Creatinine | ||
| At diagnosis | 1.2 (0.4-5.7) | 1.2 (0.4-18.6) |
| At transplant | 0.9 (0.4-4.5) | 0.9 (0.4-3.5) |
| Albumin | ||
| At diagnosis | 3.7 (2.3-5.8) | 3.7 (2.3-5.3) |
| At transplant | 3.3 (1.9-4.8) | 3.4 (2-4.9) |
| FISH, n (%) | Available in 54 pts | Available in 87 pts |
| High-risk FISH | 7 (13%) | 15 (17%) |
| t(4,14) | 2 | 7 |
| t(14,16) | 2 | 1 |
| t(14,20) | 1 | 0 |
| Deletion 17p/mono 17 | 2 | 10 |
| ISS stage, n (%) | Available in 63 pts | Available in 94 pts |
| Stage 1 | 29 (46%) | 32 (34%) |
| Stage 2 | 13 (21%) | 27 (29%) |
| Stage 3 | 21 (33%) | 35 (37%) |
| Induction regimen, n (%) | ||
| Non-novel agent based | 78 (47%) | 87 (33%) |
| Novel agent based | 89 (53%) | 176 (67%) |
| Thalidomide based | 39 (23%) | 74 (28%) |
| Lenalidomide based | 43 (26%) | 76 (29%) |
| Bortezomib based | 17 (10%) | 42 (16%) |
| Conditioning regimen, n (%) | ||
| Melphalan 200 | 143 (86%) | 216 (82%) |
| Reduced dose Melphalan | 14 (8%) | 38 (14%) |
| Other (Mel/TBI, Zevalin/Mel) | 10 (6%) | 9 (4%) |
| IMWG status, n (%) | ||
| At transplant | ||
| CR | 3 (2%) | 13 (5%) |
| VGPR | 19 (11%) | 38 (14%) |
| PR | 93 (56%) | 123 (47%) |
| SD | 47 (28%) | 64 (24%) |
| PD | 5 (3%) | 15 (6%) |
| Missing | — | 10 (4%) |
| At day 100 | ||
| VGPR | 80 (48%) | 141 (54%) |
| PR | 77 (46%) | 109 (41%) |
| SD | 10 (6%) | 13 (5%) |
| At best continued response | ||
| sCR | 28 (17%) | — |
| CR | 55 (33%) | |
| VGPR | 37 (22%) | |
| PR | 43 (26%) | |
| SD | 4 (2%) | |
| History of antecedent PC disorder | 60 (36%) | 57 (22%) |
| . | Continued response (n = 167) . | No continued response (n = 263) . |
|---|---|---|
| Variables . | Median (range) . | Median (range) . |
| Age, y | 60 (32-75) | 60 (29-74) |
| Male, n,( %) | 92 (55%) | 176 (62%) |
| PCLI | ||
| At diagnosis | 0.4 (0-4) | 0.6 (0-14.4) |
| At transplant | 0.3 (0-6) | 0.2 (0-11) |
| Serum M spike | ||
| At diagnosis | 3.7 (0-9) | 3.1 (0-8.5) |
| At transplant | 1 (0-5.1) | 1 (0-6.9) |
| Urine M spike | ||
| At diagnosis | 0.4 (0-15.5) | 0.7 (0-22.6) |
| At transplant | 0.04 (0-10) | 0.09 (0-10) |
| BMPC, % | ||
| At diagnosis | 50 (2- 95) | 50 (2-100) |
| At transplant | 11 (1-95) | 17 (1-100) |
| LDH | ||
| At diagnosis | 150 (62-464) | 152 (51-617) |
| At transplant | 205 (68-1103) | 203 (74-729) |
| β2-microglobulin | ||
| At diagnosis | 3.6 (1-1447) | 3.9 (1-21) |
| At transplant | 2.4 (1-34) | 2.5 (1-34) |
| Creatinine | ||
| At diagnosis | 1.2 (0.4-5.7) | 1.2 (0.4-18.6) |
| At transplant | 0.9 (0.4-4.5) | 0.9 (0.4-3.5) |
| Albumin | ||
| At diagnosis | 3.7 (2.3-5.8) | 3.7 (2.3-5.3) |
| At transplant | 3.3 (1.9-4.8) | 3.4 (2-4.9) |
| FISH, n (%) | Available in 54 pts | Available in 87 pts |
| High-risk FISH | 7 (13%) | 15 (17%) |
| t(4,14) | 2 | 7 |
| t(14,16) | 2 | 1 |
| t(14,20) | 1 | 0 |
| Deletion 17p/mono 17 | 2 | 10 |
| ISS stage, n (%) | Available in 63 pts | Available in 94 pts |
| Stage 1 | 29 (46%) | 32 (34%) |
| Stage 2 | 13 (21%) | 27 (29%) |
| Stage 3 | 21 (33%) | 35 (37%) |
| Induction regimen, n (%) | ||
| Non-novel agent based | 78 (47%) | 87 (33%) |
| Novel agent based | 89 (53%) | 176 (67%) |
| Thalidomide based | 39 (23%) | 74 (28%) |
| Lenalidomide based | 43 (26%) | 76 (29%) |
| Bortezomib based | 17 (10%) | 42 (16%) |
| Conditioning regimen, n (%) | ||
| Melphalan 200 | 143 (86%) | 216 (82%) |
| Reduced dose Melphalan | 14 (8%) | 38 (14%) |
| Other (Mel/TBI, Zevalin/Mel) | 10 (6%) | 9 (4%) |
| IMWG status, n (%) | ||
| At transplant | ||
| CR | 3 (2%) | 13 (5%) |
| VGPR | 19 (11%) | 38 (14%) |
| PR | 93 (56%) | 123 (47%) |
| SD | 47 (28%) | 64 (24%) |
| PD | 5 (3%) | 15 (6%) |
| Missing | — | 10 (4%) |
| At day 100 | ||
| VGPR | 80 (48%) | 141 (54%) |
| PR | 77 (46%) | 109 (41%) |
| SD | 10 (6%) | 13 (5%) |
| At best continued response | ||
| sCR | 28 (17%) | — |
| CR | 55 (33%) | |
| VGPR | 37 (22%) | |
| PR | 43 (26%) | |
| SD | 4 (2%) | |
| History of antecedent PC disorder | 60 (36%) | 57 (22%) |
PR, partial response; sCR, stringent complete response, SD, stable disease; VGPR, very good partial response.